With the support of policies, the scale of biomedical industry will be further expanded in the future
-
Last Update: 2020-02-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
[policies and regulations of pharmaceutical network] recently, Qingdao issued the notice on several policies and measures to support the high-quality development of biomedical industry From the perspective of policy content, it not only considers the urgent needs of enterprises, but also the current situation of the industry and future development, and covers the whole industrial chain of new drug research and development, industrialization, project investment, platform construction, market sales, etc It is understood that there are ten supporting policies in the circular, which are divided into four parts: encouraging R & D innovation, supporting industrial development, helping to develop market and building industrial ecology Among them, vigorously encouraging industrial innovation is the highlight of the policy, and a single drug variety from new drug research and development to industrialization can receive up to 50 million yuan of funding With such a strong support for the development of biomedical industry, it can be seen that Qingdao has a very good prospect for the development of the industry In fact, in recent years, biopharmaceutical industry is indeed becoming one of the fastest growing sub industries in the pharmaceutical industry According to the data, the global market size is expected to increase from $202 billion in 2016 to $326 billion in 2022, with a compound annual growth rate of 3% The industry expects that China's biopharmaceuticals will maintain an annual compound growth rate of 16.4% from 2016 to 2021, and reach a market scale of 326.9 billion yuan by 2021 At present, the huge market prospect has also made Biopharmaceutics gradually become an important part of the national development of the new economy, as well as an indispensable part of the innovation and development strategy Therefore, the biomedical industry has begun to usher in the era of policy dividend For example, as early as in the 13th five year plan for the development of biological industry, the state has made it clear that since the 12th Five Year Plan, the compound growth rate of China's biological industry has reached more than 15%, and the industrial scale in 2015 has exceeded 3.5 trillion yuan By 2020, the scale of biological industry will reach 8-10 trillion yuan, and the added value of biological industry will account for more than 4% of GDP, becoming the leading industry of national economy In addition to the national unified development plan, in recent years, provinces and cities have also introduced a series of relevant policies according to their own actual situation For example, on November 28, 2019, Hebei Province held a press conference to publicly release "some policies on supporting the high-quality development of biomedical industry" to the public, proposing that we should start from four aspects: breaking the bottleneck constraints of industrial development, strengthening the research and development of new drugs and technological innovation, supporting enterprises to become stronger and better, and optimizing the industrial development ecology, and improve health through 26 policies and measures The scale and quality of the development of the biomedical industry will accelerate the development of Hebei into a strong province of biomedical industry On November 14, 2019, Yunnan Province issued several opinions on accelerating the high-quality development of biomedical industry, which put forward that it will make every effort to build a core area dominated by Kunming biomedical industry cluster, and strive to double the main business income of the biomedical industry compared with 2018, reaching a scale of 100 billion yuan by 2022 In July 2019, Shanghai released the implementation opinions of General Office of Shanghai Municipal People's Government on promoting the healthy development of biomedical industry, which clearly stated that it would support the scientific and technological innovation of biomedical enterprises, support the construction of public technical service platform of biomedical industry, and promote the scale development of biomedical enterprises On the whole, China's biomedical industry will enter a golden development period with the favorable policies and the continuous breakthrough of biomedical industry technology However, due to the characteristics of "long cycle, high investment, high risk and high return" of biomedicine, the biotechnology enterprises with more mature R & D drug development in the future may occupy more market shares in the industry
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.